These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29409309)

  • 41. The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.
    Taki S; Tamai H; Ida Y; Shingaki N; Kawashima A; Shimizu R; Moribata K; Maekita T; Iguchi M; Kato J; Nakao T; Kitano M
    Gut Liver; 2018 Jan; 12(1):86-93. PubMed ID: 28798288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
    Everson GT; Sims KD; Thuluvath PJ; Lawitz E; Hassanein T; Rodriguez-Torres M; Desta T; Hawkins T; Levin JM; Hinestrosa F; Rustgi V; Schwartz H; Younossi Z; Webster L; Gitlin N; Eley T; Huang SP; McPhee F; Grasela DM; Gardiner DF
    Liver Int; 2016 Feb; 36(2):189-97. PubMed ID: 26473667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
    Kato K; Shimada N; Atsukawa M; Abe H; Itokawa N; Matsumoto Y; Agata R; Tsubota A
    PLoS One; 2019; 14(7):e0219022. PubMed ID: 31291311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
    Jensen D; Sherman KE; Hézode C; Pol S; Zeuzem S; de Ledinghen V; Tran A; Elkhashab M; Younes ZH; Kugelmas M; Mauss S; Everson G; Luketic V; Vierling J; Serfaty L; Brunetto M; Heo J; Bernstein D; McPhee F; Hennicken D; Mendez P; Hughes E; Noviello S;
    J Hepatol; 2015 Jul; 63(1):30-7. PubMed ID: 25703086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
    Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
    J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
    Mawatari S; Oda K; Tabu K; Ijuin S; Kumagai K; Inada Y; Uto H; Hiramine Y; Kure T; Fujisaki K; Hashiguchi M; Hori T; Oshige A; Imanaka D; Saishoji A; Taniyama O; Sakae H; Tamai T; Moriuchi A; Ido A
    J Gastroenterol; 2017 Jul; 52(7):855-867. PubMed ID: 28078469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
    Yu JH; Lee JI; Lee KS; Kim JK
    Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
    Akuta N; Sezaki H; Suzuki F; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Jan; 89(1):91-98. PubMed ID: 27256744
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test.
    Jang ES; Kim KA; Kim YS; Kim IH; Lee BS; Lee YJ; Chung WJ; Jeong SH
    J Med Virol; 2019 Dec; 91(12):2158-2165. PubMed ID: 31452206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
    Cho BW; Kim SB; Song IH; Lee SH; Kim HS; Lee TH; Kang YW; Kim SH; Lee BS; Chae HB
    Clin Mol Hepatol; 2017 Mar; 23(1):51-56. PubMed ID: 28297836
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
    Ikeda H; Watanabe T; Okuse C; Matsumoto N; Ishii T; Yamada N; Shigefuku R; Hattori N; Matsunaga K; Nakano H; Hiraishi T; Kobayashi M; Yasuda K; Yamamoto H; Yasuda H; Kurosaki M; Izumi N; Yotsuyanagi H; Suzuki M; Itoh F
    J Med Virol; 2017 Jan; 89(1):99-105. PubMed ID: 27329864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
    Liu Y; Wang Z; Tobe RG; Lin H; Wu B
    Clin Drug Investig; 2018 May; 38(5):427-437. PubMed ID: 29417464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
    Kumada H; Suzuki F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Fujiyama S; Ito T; Itoh Y; Tamura E; Ueki T; Ishikawa H; Hu W; McPhee F; Linaberry M; Hughes E
    J Gastroenterol Hepatol; 2016 Jan; 31(1):14-22. PubMed ID: 26252875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
    Cordie A; Elsharkawy A; Abdel Alem S; Meshaal S; El Akel W; Abdellatif Z; Kamal W; Al Askalany M; Kamel S; Abdel Aziz H; Kandeel A; Esmat G
    Trans R Soc Trop Med Hyg; 2020 Apr; 114(4):232-240. PubMed ID: 31925434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
    Wei L; Zhang M; Xu M; Chuang WL; Lu W; Xie W; Jia Z; Gong G; Li Y; Bae SH; Yang YF; Xie Q; Lin S; Chen X; Niu J; Jia J; Garimella T; Torbeyns A; McPhee F; Treitel M; Yin PD; Mo L
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1860-1867. PubMed ID: 27003037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
    Morisawa N; Koshima Y; Satoh JI; Maruyama Y; Kuriyama S; Yokoo T; Amemiya M
    Clin Exp Nephrol; 2017 Oct; 21(5):818-824. PubMed ID: 27771774
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.
    Zeuli JD; Adie SK; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2015 Nov; 51(11):629-43. PubMed ID: 26744738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type C.
    Hagiwara S; Nishida N; Watanabe T; Sakurai T; Ida H; Minami Y; Takita M; Minami T; Iwanishi M; Chishina H; Ueshima K; Komeda Y; Arizumi T; Kudo M
    Dig Dis; 2016; 34(6):620-626. PubMed ID: 27750228
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    Ahmed AM; Doheim MF; Mattar OM; Sherif NA; Truong DH; Hoa PTL; Hirayama K; Huy NT
    J Med Virol; 2018 May; 90(5):907-918. PubMed ID: 28892235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
    Hong CM; Liu CJ; Yeh SH; Chen PJ
    J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.